Sector: Health Care
Director information for BIOMARIN PHARMACEUTICAL INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Alexander Hardy | President and Chief Executive Officer | 57 | ["extensive experience in the global biopharmaceutical industry","management of biotechnology organizations","business development","leadership expertise","sales and marketing of both biotechnology and pharmaceutical products","more than 30 years in the global pharmaceutical industry","served as Chief Executive Officer of Genentech, Inc.","various leadership roles at Genentech, Inc. and Novartis"] | [] | 2026 |
| Athena Countouriotis, M.D. | Avenzo Therapeutics; President | 54 | ["Director, Iovance Biotherapeutics, Inc.","Director, Passage Bio, Inc.","extensive experience in managing biotechnology, pharmaceutical and clinical organizations","expertise in research and clinical development","led oncology company through its initial public offering","previously served as Senior Vice President and Chief Medical Officer in multiple organizations","held various clinical development roles within Pfizer Inc. and Bristol-Myers Squibb Company"] | [] | 2026 |
| Barbara W. Bodem | Director, Enovis Corp. | 58 | ["Director, Option Care Health, Inc.","extensive experience serving on the boards of biotechnology and pharmaceutical organizations","financial and accounting expertise","interim Chief Financial Officer of Dentsply Sirona Inc.","Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc.","Senior Vice President of Finance of Mallinckrodt Pharmaceuticals","senior finance roles at Hospira, Inc. and Eli Lilly and Company","holds a B.S. in Finance","M.B.A from Indiana University"] | [] | 2026 |
| Cristin Hubbard | Executive Vice President and Chief Commercial Officer | 50 | ["More than 20 years in the biopharmaceutical and diagnostics industries","Head of Global Product Strategy for Roche Pharmaceuticals","Lifecycle management and global commercial strategy","16 years at Roche and Genentech in leadership positions","Medicinal chemist at Theravance Biopharma, Inc.","B.S. in Biochemistry and Molecular Biology from the University of California, Santa Cruz","MBA from the Haas School of Business","MPH from the School of Public Health"] | ["Board of Directors of the Biotechnology Innovation Organization (BIO)"] | 2026 |
| Elizabeth McKee Anderson | Director, GSK PLC | 68 | ["Director, Insmed, Inc.","Director, Revolution Medicines, Inc.","extensive experience in managing large biotechnology and pharmaceutical organizations","compensation and corporate governance matters","finance and accounting","sales and marketing of both biotechnology and pharmaceutical products","held various senior leadership positions at Johnson & Johnson from 2003 to 2014","Vice President and General Manager of Wyeth Lederle Vaccines","served on the boards of GSK plc, Insmed, Inc., Revolution Medicines, Inc., Bavarian Nordic A/S, and Huntsworth PLC"] | ["Compensation Committee"] | 2026 |
| Henry J. Fuchs, M.D. | [] | [] | 2026 | ||
| Ian T. Clark | Director, Takeda Pharmaceutical Company Limited(1); Chair of the Board | 65 | ["Director, Olema Pharmaceuticals, Inc.","Director, Kyverna Therapeutics, Inc.","Director, Corvus Pharmaceuticals, Inc.","Director, Guardant Health, Inc.","Extensive experience serving as an executive and on the boards of directors of many public and private companies in the biopharmaceutical industry","Chief Executive Officer of Genentech Inc.","Held senior management positions at Genentech/Roche","23 years in the biopharmaceutical industry in senior roles at Novartis International AG, Sanofi S.A., Ivax Pharmaceuticals and G.D. Searle","Advisor to KKR & Co. Inc.","extensive experience serving as an executive","experience on the boards of directors of many public and private companies","expertise in the biopharmaceutical industry"] | [] | 2026 |
| Mark J. Enyedy | ImmunoGen, Inc.; Director | 62 | ["Director, Charles River Laboratories International, Inc.","Director, Astellas Pharma Inc.","extensive experience in general management","business development","corporate and securities law in the biotechnology industry","served as President and Chief Executive Officer of ImmunoGen, Inc.","served in various executive capacities at Shire plc","CEO and director of Proteostasis Therapeutics, Inc.","15 years at Genzyme Corporation","Associate with the Boston law firm Palmer & Dodge"] | ["CGN Committee"] | 2026 |
| Maykin Ho, Ph.D. | Director, Agios Pharmaceuticals, Inc. | 73 | ["Director, Kyntra Bio, Inc.","Director, Neumora Therapeutics, Inc.","extensive experience in healthcare investment research","finance","analysis of science and biotechnology","Venture Partner of Aulis Capital","retired partner of the Goldman Sachs Group","senior biotechnology analyst","co-head of Global Healthcare Investment Research","advisory director for Healthcare Investment Banking","various managerial positions in licensing, strategic planning, marketing and research at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company","venture partner of Qiming Venture Partners","Ph.D. in Microbiology and Immunology","B.S. from the State University of New York, Downstate Medical Center","postdoctoral fellow at Harvard Medical School","graduate of the Advanced Management Program at The Fuqua School of Business, Duke University"] | [] | 2026 |
| Robert J. Hombach | Baxalta Inc.; Director | 60 | ["Director, Embecta Corporation","Director, Henry Schein, Inc.(2)","Extensive experience in finance and accounting","Capital markets","Managing large biotechnology and pharmaceutical organizations","Former Executive Vice President, CFO & COO at Baxalta Inc.","Served as Vice President and Chief Financial Officer at Baxter","Held various finance positions at Baxter"] | ["Audit Committee"] | 2026 |
| Timothy P. Walbert | Horizon Therapeutics; Former Chairman, President and Chief Executive Officer | 59 | ["Senior Advisor, Amgen","Director, Mirum Pharmaceuticals, Inc.","Director, Century Therapeutics, Inc.","Director, Sagimet Biosciences Inc.","extensive experience in the biotechnology industry","executive-level leadership","sales and marketing of biotechnology and pharmaceutical products"] | [] | 2026 |
| Willard Dere, M.D. | University of Utah; Director | 72 | ["Chief Advisor to the CEO and Chief Medical Officer, Angitia Biopharmaceuticals","Director, Seres Therapeutics, Inc.","Director, Metagenomi, Inc.","Professor Emeritus of Internal Medicine at the University of Utah","Chief Advisor to the CEO and Chief Medical Officer at Angitia Biopharmaceuticals","25 years in the biopharmaceutical industry","Multiple roles at Amgen, Inc. and Eli Lilly and Company","Co-Director of the Utah Clinical and Translational Science Institute","B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research"] | ["Science and Technology Committee"] | 2026 |
